However, the effect of adjunctive vorapaxar therapy was consistent with the overall
trial results, with no interaction between drug
and management strategy on the primary
(p for interaction = 0.75), key secondary (p for
interaction = 0.58) and primary safety (p for
interaction = 0.80) end points [54].